RPRX · NASDAQ · STOCK
Royalty Pharma (RPRX) Stock Analysis
$59.84
52W $35.79 – $64.38
55/100
$25.08B
23.5
0.41
Is RPRX Bullish or Bearish?
Mixed.
Innellis AI committee rates Royalty Pharma plc (RPRX) Watch with a composite score of 55/100
, based on 5 analysts with 60% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.08 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Dividend yield of 3.0% pays you to wait — Value
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 39.9 is moderate-to-rich — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
- News sentiment is negative (-0.17 across 6 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
55/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 67%
of 192 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 3.0% pays you to wait
− P/E of 39.9 is moderate-to-rich
Growth Analyst
bullish
62
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -15.9% YoY despite any revenue growth
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
52
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.17 across 6 articles, 14d)
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 56.2 to 55.1.
- Conviction changed from contested to moderate.
- Committee agreement increased sharply from 40% to 60%.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Value Analyst.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- News Analyst: +1 bearish signal(s).
- Portfolio Manager: score 30->35 (+5).
- Value Analyst: stance bearish->neutral; score 38->48 (+10); +1 bearish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
62.5
Neutral
MACD Histogram
0.124
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$51.15
Resistance
$64.37
Bollinger %B
0.86
Inside Bands
Price vs Moving Averages
EMA 9
$57.47
Above
EMA 21
$57.90
Above
EMA 50
$58.25
Above
EMA 200
$52.53
Above
Fundamental Analysis
Valuation
44
Growth
74
Profitability
75
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
23.5×
P/B Ratio
3.68×
PEG Ratio
6.84
Dividend Yield
1.64%
52W High
$64.38
52W Low
$35.79
Quality & Growth
ROE
1190.3%
ROA
392.9%
Gross Margin
8937.8%
Operating Margin
6234.3%
Revenue Growth YoY
—
Debt / Equity
1.31
AI Fundamental Assessment
P/E ratio of 23.5 (inexpensive relative to a 15-40x range); Price-to-book of 3.7x; PEG ratio of 6.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.9%; Return on assets of 3.9%; Net margin of 32.1%; Gross margin of 89.4%; Current ratio of 1.29 (tight short-term liquidity); Debt-to-equity of 1.31; Free cash flow per share is positive (6.69); Most recent quarter beat estimates by 1.3%; 4 consecutive earnings beats; EPS growth accelerating (-11.6% -> +1.5% QoQ); Analyst estimates falling over recent quarters
Get the Full RPRX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →